Publication

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…

CertaraJanuary 22, 2026

On-Demand Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…

CertaraJanuary 22, 2026

Blog

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

Leveraging adaptive clinical trial designs in oncology can accelerate drug development, while following the FDA…

CertaraJanuary 16, 2026

Webinar

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

CertaraJanuary 14, 2026

On-Demand Webinar

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

Watch this on-demand webinar featuring former regulators as they share global regulatory trends and clinical…

CertaraJanuary 14, 2026

Publication

Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open-Label, Crossover, Randomized, Controlled, Phase I Clinical Trial

Find out how RL001 delivers >1000 mg tablet exposure with reduced food effect and improved…

CertaraJanuary 1, 2026

Publication

Pharmacokinetics, Bioequivalence, and Safety of Diclofenac Sodium Sustained-Release Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Explore how two replicated trials confirm diclofenac SR test and reference tablets are bioequivalent under…

CertaraJanuary 1, 2026

Blog

Delivering on deadline: Why pharmacometrics (pmx) is the anchor of successful regulatory submissions

Explore how PMx regulatory submissions, exposure-response modeling, and strategic pharmacometrics planning support successful and timely…

CertaraDecember 29, 2025

Conference

MVA Oncology Network

CertaraDecember 19, 2025

Publication

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

This study synthesizes data from a large body of clinical trials to evaluate rates of…

CertaraDecember 18, 2025

Clinical Pharmacology

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open-Label, Crossover, Randomized, Controlled, Phase I Clinical Trial

Pharmacokinetics, Bioequivalence, and Safety of Diclofenac Sodium Sustained-Release Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Delivering on deadline: Why pharmacometrics (pmx) is the anchor of successful regulatory submissions

MVA Oncology Network

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

Newsletter sign up

Quick links

Solutions

Contact